Jefferies Assumes POINT Biopharma Global at Buy, Raises Price Target to $14
Portfolio Pulse from richadhand@benzinga.com
Jefferies analyst Chris Howerton has assumed POINT Biopharma Global (NASDAQ:PNT) with a Buy rating and raised the price target to $14.
July 20, 2023 | 4:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies has given POINT Biopharma Global a Buy rating and raised the price target to $14, indicating positive sentiment towards the stock.
The Buy rating and increased price target from Jefferies indicate a positive outlook for POINT Biopharma Global. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100